ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by ArriVent BioPharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for ArriVent BioPharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Peterson Kristine | Director | – | Jun 22, 2026 | 1 |
| Hohneker John | Director | – | Jun 22, 2026 | 1 |
| Nolet Chris | Director | – | Jun 22, 2026 | 1 |
| Parsey Merdad | Director | – | Jun 22, 2026 | 1 |
| Yao Zhengbin | President and CEO | – | Feb 4, 2026 | 1 |
| Kung Winston | Chief Financial Officer | – | Feb 4, 2026 | 1 |
| Kastenmayer James Paul | General Counsel | – | Feb 4, 2026 | 1 |
| LaChapelle Robin | Chief Operating Officer | 135,736 | Feb 4, 2026 | 1 |
| Lutzker Stuart | President of R&D | – | Feb 4, 2026 | 1 |
| Hillhouse Investment Management, Ltd. | 10% Owner | 3,929,117Indirect | Feb 3, 2026 | 1 |
| HHLR Advisors, Ltd. | 10% Owner | 3,929,117Indirect | Feb 3, 2026 | 1 |
| OrbiMed Advisors LLC | Director, 10% Owner | 1,513,664Indirect | Jan 31, 2024 | 0 |
| OrbiMed Capital GP VIII LLC | Director, 10% Owner | 1,513,664Indirect | Jan 31, 2024 | 0 |
| OrbiMed Advisors IV Ltd | Director, 10% Owner | 1,513,664Indirect | Jan 31, 2024 | 0 |
| OrbiMed Asia GP IV, L.P. | Director, 10% Owner | 1,513,664Indirect | Jan 31, 2024 | 0 |
| Healy James | Director | 1,696,752Indirect | Jan 31, 2024 | 0 |
| Gordon Carl L | Director, 10% Owner | 1,513,664Indirect | Jan 31, 2024 | 0 |
| Jallal Bahija | Director | – | Jan 29, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 (view filing)4:05 PM ET | Dec 10, 2025 | 55 daysLate | Hillhouse Investment Management, Ltd. and 1 other10% Owner | SSale | −555.6K | $23.37 | −$13.0M | −12.4%3.93M after | |
| Feb 1, 2024 (view filing)4:47 PM ET | Jan 30 | 2 days | Hillhouse Investment Management, Ltd. and 1 other10% Owner | PPurchase | +555.6K | $18.00 | +$10.0M | +14.1%4.48M after | |
| Jan 31, 2024 (view filing)4:12 PM ET | Jan 30 | 1 day | OrbiMed Advisors LLC and 3 othersDirector, 10% Owner | PPurchase | +444.4K | $18.00 | +$8.00M | +41.6%1.51M after | 2 lotsDuplicate filing |
| Jan 31, 2024 (view filing) | Jan 30 | 1 day | Gordon Carl LDirector, 10% Owner | PPurchase | +444.4K | $18.00 | +$8.00M | +41.6%1.51M after | 2 lots |
| Jan 31, 2024 (view filing) | Jan 30 | 1 day | Healy JamesDirector | PPurchase | +444.4K | $18.00 | +$8.00M | +35.5%1.70M after |